B Lymphocyte Stimulator-directed Antibody Interactions [MoA] - N0000182636
Pharmacologic Class Information
| Pharmacologic Code | N0000182636 |
| Pharmacologic Name | B Lymphocyte Stimulator-directed Antibody Interactions |
| Pharmacologic Uses |
|
| Pharmacologic Concept | Mechanisms of Action - [MoA] |
| Pharmacologic Concept Description | This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept. |
NDC Products with B Lymphocyte Stimulator-directed Antibody Interactions
The table contains 3 products whose active ingredient are classified under the same pharmacologic class B Lymphocyte Stimulator-directed Antibody Interactions [MoA].
| NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
|---|---|---|---|---|---|---|---|
| 49401-088 | Benlysta | Non-Proprietary Name: Belimumab | Solution | Subcutaneous | Glaxosmithkline Llc | ACTIVE | |
| 49401-101 | Benlysta | Non-Proprietary Name: Belimumab | Injection, Powder, Lyophilized, For Solution | Intravenous | Glaxosmithkline Llc | ACTIVE | |
| 49401-102 | Benlysta | Non-Proprietary Name: Belimumab | Injection, Powder, Lyophilized, For Solution | Intravenous | Glaxosmithkline Llc | ACTIVE |